The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research
Abstract
MDMA (3,4‐methylenedioxymethamphetamine) or ‘Ecstasy’ was scheduled as an illegal drug in 1986, but since then its recreational use has increased dramatically. This review covers 15 years of research into patterns of use, its acute psychological and physiological effects, and the long‐term consequences of repeated use. MDMA is an indirect monoaminergic agonist, stimulating the release and inhibiting the reuptake of serotonin (5‐HT) and, to a lesser extent, other neurotransmitters. Single doses of MDMA have been administered to human volunteers in double‐blind placebo‐controlled trials, although most findings are based upon recreational MDMA users. The ‘massive’ boost in neurotransmitter activity can generate intense feelings of elation and pleasure, also hyperactivity and hyperthermia. This psychophysiological arousal may be exacerbated by high ambient temperatures, overcrowding, prolonged dancing and other stimulant drugs. Occasionally the ‘serotonin syndrome’ reactions may prove fatal. In the days after Ecstasy use, around 80% of users report rebound depression and lethargy, due probably to monoaminergic depletion. Dosage escalation and chronic pharmacodynamic tolerance typically occur in regular users. Repeated doses of MDMA cause serotonergic neurotoxicity in laboratory animals, and there is extensive evidence for long‐term neuropsychopharmacological damage in humans. Abstinent regular Ecstasy users often display reduced levels of 5‐HT, 5‐HIAA, tryptophan hydroxylase and serotonin transporter density; functional deficits in learning/memory, higher cognitive processing, sleep, appetite and psychiatric well‐being, and, most paradoxically, ‘loss of sexual interest/pleasure’. These psychobiological deficits are greatest in heavy Ecstasy users and may reflect serotonergic axonal loss in the higher brain regions, especially the frontal lobes, temporal lobes and hippocampus. These problems seem to remain long after the recreational use of Ecstasy has ceased, suggesting that the neuropharmacological damage may be permament. Copyright © 2001 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")
Henry, J. A., Jeffreys, K. J., & Dawling, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)91469-o · Cited by 729
McCann, U., Szabo, Z., Scheffel, U., Dannals, R., & Ricaurte, G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04329-3 · Cited by 660
Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
Schmidt, C. J. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22673-8 · Cited by 529
Alcohol and drug use in UK university students
Webb, E., Ashton, C., Kelly, P., & Kamali, F. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03410-1 · Cited by 472
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Does cigarette smoking cause stress?
Parrott, A. C. (1999) · American Psychologist · doi:10.1037/0003-066x.54.10.817 · Cited by 447
Self-citationGreen, A. R., Cross, A. J., & Goodwin, G. M. (1995) · Psychopharmacology · doi:10.1007/bf02246288 · Cited by 415
Subjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413
Recreational MDMA use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug
SOLOWIJ, N., HALL, W., & LEE, N. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb02003.x · Cited by 413
Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans
De La Torre, R., Farré, M., Ortuño, J., Mas, M., Brenneisen, R., Roset, P. N., Segura, J., & Camí, J. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00121.x · Cited by 401
Ecstasy (MDMA): a review of its possible persistent psychological effects
Morgan, M. J. (2000) · Psychopharmacology · doi:10.1007/s002130000545 · Cited by 380
Memory impairment in abstinent MDMA ("Ecstasy") users
Bolla, K. I., McCann, U. D., & Ricaurte, G. A. (1998) · Neurology · doi:10.1212/wnl.51.6.1532 · Cited by 373
Hallucinogenic Amphetamine Selectively Destroys Brain Serotonin Nerve Terminals
Ricaurte, G., Bryan, G., Strauss, L., Seiden, L., & Schuster, C. (1985) · Science · doi:10.1126/science.4023719 · Cited by 367
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Ecstasy use in Australia: patterns of use and associated harm
Topp, L., Hando, J., Dillon, P., Roche, A., & Solowij, N. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00002-2 · Cited by 352
Malberg, J. E., & Seiden, L. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-13-05086.1998 · Cited by 344
Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance
Parrott, A. C., & Lasky, J. (1998) · Psychopharmacology · doi:10.1007/s002130050714 · Cited by 340
Self-citationMcCann, U. D., Ridenour, A., Shaham, Y., & Ricaurte, G. A. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.15 · Cited by 332
Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity
Parrott, A. C. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00711-0 · Cited by 324
Self-citation(1988) · PubMed · Cited by 313
MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons
Battaglia, G., Yeh, S. Y., & De Souza, E. B. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90155-4 · Cited by 312
The serotonin syndrome and its treatment
Gillman, P. K. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300111 · Cited by 306
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
Gouzoulis-Mayfrank, E. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.719 · Cited by 305
McCann, U. D., Mertl, M., Eligulashvili, V., & Ricaurte, G. A. (1999) · Psychopharmacology · doi:10.1007/s002130050967 · Cited by 300
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals
Ricaurte, G. A., Yuan, J., & McCann, U. D. (2000) · Neuropsychobiology · doi:10.1159/000026664 · Cited by 292
Recreational Use of “Ecstasy” (MDMA) Is Associated with Elevated Impulsivity
Morgan, M. J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00012-8 · Cited by 288
CURRAN, H. V., & TRAVILL, R. A. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb02951.x · Cited by 282
Memory deficits associated with recreational use of "ecstasy" (MDMA)
Morgan, M. J. (1999) · Psychopharmacology · doi:10.1007/s002130050803 · Cited by 281
Semple, D. M., Ebmeier, K. P., Glabus, M. F., O'Carroll, R. E., & Johnstone, E. C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.63 · Cited by 280
Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users
Parrott, A. C., Sisk, E., & Turner, J. J. D. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)80013-7 · Cited by 279
Self-citationFischer, C., Hatzidimitriou, G., Wlos, J., Katz, J., & Ricaurte, G. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-08-05476.1995 · Cited by 268
A review of the role of serotonin receptors in psychiatric disorders
Naughton, M., Mulrooney, J. B., & Leonard, B. E. (2000) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/1099-1077(200008)15:6<397::aid-hup212>3.0.co;2-l · Cited by 258
Tucker, G. T., Lennard, M. S., Ellis, S. W., Woods, H. F., Cho, A. K., Lin, L. Y., Hiratsuka, A., Schmitz, D. A., & Chu, T. Y. Y. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90386-7 · Cited by 236
Liechti, M. E., & Vollenweider, F. X. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.348 · Cited by 236
The Background and Chemistry of MDMA
Shulgin, A. T. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472361 · Cited by 233
Cognitive performance and serotonergic function in users of ecstasy
Verkes, R. J., Gijsman, H. J., Pieters, M. S. M., Schoemaker, R. C., de Visser, S. J., Kuijpers, M., Pennings, E. J. M., de Bruin, D., van de Wijngaart, G. F., van Gerven, J., et al. (2001) · Psychopharmacology · doi:10.1007/s002130000563 · Cited by 233
Schmitt, J. A. J., Jorissen, B. L., Sobczak, S., van Boxtel, M. P. J., Hogervorst, E., Deutz, N. E. P., & Riedel, W. J. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400102 · Cited by 227
The relative contributions of ecstasy and cannabis to cognitive impairment
Croft, R. J., Mackay, A. J., Mills, A. T. D., & Gruzelier, J. G. H. (2001) · Psychopharmacology · doi:10.1007/s002130000591 · Cited by 225
Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits
Parrott, A. C., Lees, A., Garnham, N. J., Jones, M., & Wesnes, K. A. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200110 · Cited by 219
Self-citationCognitive performance amongst recreational users of "ecstasy"
Rodgers, J. (2000) · Psychopharmacology · doi:10.1007/s002130000467 · Cited by 218
Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat
Gordon, C. J., Watkinson, W. P., O'Callaghan, J. P., & Miller, D. B. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90288-d · Cited by 216
MDMA (`ecstasy') consumption in the context of polydrug abuse: a report on 150 patients
Schifano, F., Furia, L. D., Forza, G., Minicuci, N., & Bricolo, R. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00051-9 · Cited by 216
The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?
Bantick, R. A., Deakin, J. F. W., & Grasby, P. M. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500108 · Cited by 214
Berger, U. V., Gu, X. F., & Azmitia, E. C. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90023-w · Cited by 210
Reneman, L., Booij, J., Schmand, B. A., van den Brink, W., & Gunning, B. W. (2000) · Psychopharmacology · doi:10.1007/s002130050057 · Cited by 210
Parrott, A. C., Milani, R. M., Parmar, R., & Turner, J. J. (2001) · Psychopharmacology · doi:10.1007/s002130100897 · Cited by 210
Self-citationEcstasy and new patterns of drug use: a normal population study
Pedersen, W., & Skrondal, A. (1999) · Addiction · doi:10.1046/j.1360-0443.1999.941116957.x · Cited by 203
Methylenedioxymethamphetamine: A potentially neurotoxic amphetamine analogue
Schmidt, C. J., Wu, L., & Lovenberg, W. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90140-8 · Cited by 202
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies
McCann, U. D., Eligulashvili, V., & Ricaurte, G. A. (2000) · Neuropsychobiology · doi:10.1159/000026665 · Cited by 190
Working memory deficits in current and previous users of MDMA (‘ecstasy’)
Wareing, M., Fisk, J. E., & Murphy, P. N. (2000) · British Journal of Psychology · doi:10.1348/000712600161772 · Cited by 186
A Method of Conducting Therapeutic Sessions with MDMA
Greer, G. R., & Tolbert, R. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399713 · Cited by 182
Sprague, J. E., Everman, S. L., & Nichols, D. E. (1998) · PubMed · Cited by 181
3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans
Hegadoren, K. M., Baker, G. B., & Bourin, M. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(98)00046-3 · Cited by 178
Cottler, L. B., Womack, S. B., Compton, W. M., & Abdallah, A. B. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.343 · Cited by 172
Fox, H. C., Parrott, A. C., & Turner, J. J. D. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500406 · Cited by 170
Self-citationKrystal, J. H., Price, L. H., Opsahl, C., Ricaurte, G. A., & Heninger, G. R. (1992) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999209026070 · Cited by 168
Serotonin syndrome: history and risk
Gillman, P. K. (1998) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00976.x · Cited by 167
Gamma, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00130-5 · Cited by 162
Parrott, A. C. (2000) · Neuropsychobiology · doi:10.1159/000026666 · Cited by 150
Self-citationGouzoulis‐Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. ‐., Lindenblatt, H., Hermle, L., Spitzer, M., & Sass, H. (1999) · Psychopharmacology · doi:10.1007/s002130050860 · Cited by 145
Serotonergic function after (±)3,4-methylene-dioxymethamphetarnine (‘Ecstasy’) in humans
Gerra, G., Zaimovic, A., Giucastro, G., Maestri, D., Monica, C., Sartori, R., Caccavari, R., & Delsignore, R. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199801000-00001 · Cited by 145
Broening, H. W., Morford, L. L., Inman-Wood, S. L., Fukumura, M., & Vorhees, C. V. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03228.2001 · Cited by 143
Curran, H. V. (2000) · Neuropsychobiology · doi:10.1159/000026668 · Cited by 142
Huether, G., Zhou, D., & R�ther, E. (1997) · Journal of Neural Transmission · doi:10.1007/bf01285547 · Cited by 134
McCann, U. D., Ricaurte, G. A., & Ciraulo, D. A. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199110000-00005 · Cited by 134
Ecstasy (MDMA) in Recreational Users: Self-Reported Psychological and Physiological Effects
DAVISON, D., & Parrott, A. C. (1997) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199705/06)12:3<221::aid-hup854>3.0.co;2-c · Cited by 134
Self-citationDifferential effects of Ecstasy and cannabis on self‐reports of memory ability: a web‐based study
Rodgers, J., Buchanan, T., Scholey, A. B., Heffernan, T., Ling, J., & Parrott, A. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.345 · Cited by 125
Self-citationMDMA and Human Sexual Function
Buffum, J. C., & Moser, C. A. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472369 · Cited by 121
Memory impairment in abstinent MDMA (“Ecstasy”) users: A longitudinal investigation
Zakzanis, K. K., & Young, D. A. (2001) · Neurology · doi:10.1212/wnl.56.7.966 · Cited by 121
Jansen, K. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00111-2 · Cited by 120
Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms
MacInnes, N., Handley, S. L., & Harding, G. F. A. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500310 · Cited by 120
Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user
Kish, S. J., Furukawa, Y., Ang, L.-C., Vorce, S. P., & Kalasinsky, K. S. (2000) · Neurology · doi:10.1212/wnl.55.2.294 · Cited by 119
Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ???Ecstasy???)
McCann, U. D., Slate, S. O., & Ricaurte, G. A. (1996) · Drug Safety · doi:10.2165/00002018-199615020-00003 · Cited by 118
Chemical Analysis of Ecstasy Pills
Baggott, M. J., Heifets, B. D., Jones, R. T., Mendelson, J., Sferios, E., & Zehnder, J. (2000) · JAMA · doi:10.1001/jama.284.17.2190 · Cited by 116
‘Ecstasy’ Psychosis and Flashbacks
Creighton, F. J., Black, D. L., & Hyde, C. E. (1991) · The British Journal of Psychiatry · doi:10.1192/bjp.159.5.713 · Cited by 114
Persistent Effects of (±)3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) on Human Sleep
Allen, R. P., McCann, U. D., & Ricaurte, G. A. (1993) · SLEEP · doi:10.1093/sleep/16.6.560 · Cited by 113
Heffernan, T., Jarvis, H., Rodgers, J., Scholey, A. B., & Ling, J. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.349 · Cited by 112
Dafters, R. I. (1994) · Psychopharmacology · doi:10.1007/bf02249342 · Cited by 106
Bellis, M. A., Hale, G., Bennett, A., Chaudry, M., & Kilfoyle, M. (2000) · International Journal of Drug Policy · doi:10.1016/s0955-3959(00)00053-0 · Cited by 105
Psychological Effects of MDE in Normal Subjects: Are Entactogens a New Class of Psychoactive Agents?
Hermle, L., Spitzer, M., Borchardt, D., Kovar, K., & Gouzoulis, E. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.19 · Cited by 104
Ricaurte, G. A., Finnegan, K. T., Irwin, I., & Langston, J. W. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16919.x · Cited by 102
Is the Use of Ecstasy and Hallucinogens Increasing?
Schuster, P. M., Lieb, R., Lamertz, C. M., & Wïttchen, H. (1998) · European Addiction Research · doi:10.1159/000018925 · Cited by 97
MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks
Boot, B. P., McGregor, I. S., & Hall, W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02276-5 · Cited by 95
Dafters, R. I., Duffy, F., O'Donnell, P. J., & Bouquet, C. (1999) · Psychopharmacology · doi:10.1007/s002130051035 · Cited by 95
Price, L. H., Ricaurte, G. A., Krystal, J. H., & Heninger, G. R. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010022003 · Cited by 93
Long term psychiatric and cognitive effects of MDMA use
McGuire, P. K. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00219-2 · Cited by 90
McCann, U., & Ricaurte, G. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00171-8 · Cited by 89
Schifano, F. (2000) · Neuropsychobiology · doi:10.1159/000026667 · Cited by 83
Soar, K., Turner, J. J., & Parrott, A. C. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.350 · Cited by 80
Self-citationChronic atypical psychosis associated with MDMA ("ecstasy") abuse
Schifano, F. (1991) · The Lancet · doi:10.1016/0140-6736(91)92633-d · Cited by 79
Deconstructing Ecstasy: The Politics Of Mdma Research
Grob, C. S. (2000) · Addiction Research & Theory · doi:10.3109/16066350008998989 · Cited by 79
MDMA: Its History and Pharmacology
McDowell, D. M., & Kleber, H. D. (1994) · Psychiatric Annals · doi:10.3928/0048-5713-19940301-06 · Cited by 73
MONITORING SYNTHETIC DRUG MARKETS, TRENDS, AND PUBLIC HEALTH
Spruit, I. P. (2001) · Substance Use & Misuse · doi:10.1081/ja-100000227 · Cited by 66
The Love Drug: Marching to the Beat of Ecstasy
Stimmel, B., & Cohen, R. S. (1998) · Medical Entomology and Zoology · Cited by 61
MDMA (“ecstasy”) abuse: Psychopathological features and craving for chocolate: A case series
Schifano, F., & Magni, G. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90088-4 · Cited by 58
McCann, U. D., & Ricaurte, G. A. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199306000-00011 · Cited by 55
Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach
Reneman, L., Booij, J., Majoie, C. B. L. M., van den Brink, W., & den Heeten, G. J. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.347 · Cited by 52
The love drug: marching to the beat of ecstasy
(1999) · Choice Reviews Online · doi:10.5860/choice.36-3357 · Cited by 49
Vollenweider, F. X., Gamma, A., Liechti, M. E., & Huber, T. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00032-9 · Cited by 45
Auditory verbal learning in drug‐free Ecstasy polydrug users
Fox, H. C., Toplis, A. S., Turner, J. J., & Parrott, A. C. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.344 · Cited by 44
Self-citationCigarette smoking does cause stress.
Parrott, A. C. (2000) · American Psychologist · doi:10.1037/0003-066x.55.10.1159 · Cited by 35
Self-citationVollenweider, F. X., Jones, R. T., & Baggott, M. J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00170-6 · Cited by 34
Ricaurte, G. A., & McCann, U. D. (2001) · Neurotoxicity Research · doi:10.1007/bf03033232 · Cited by 34
Cigarette smoking does cause distress.
Parrott, A. C. (2000) · American Psychologist · doi:10.1037//0003-066x.55.10.1159 · Cited by 33
Self-citationEcstasy Use and Policy Responses in the Netherlands
Spruit, I. P. (1999) · Journal of Drug Issues · doi:10.1177/002204269902900312 · Cited by 29
LIEBERMAN, J., & Aghajanian, G. K. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00071-8 · Cited by 23
Ecstasy, serotonin syndrome and the treatment of hyperpyrexia
Gillman, P. K. (1997) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1997.tb138798.x · Cited by 23
Ecstasy and neurodegeneration: Advice is that “less is more”
Merrill, J. (1996) · BMJ · doi:10.1136/bmj.313.7054.423 · Cited by 20
Drug Use Among College Undergraduates: Current Use and 10-Year Trends
Meilman, P. W., Gaylor, M. S., Turco, J. H., & Stone, J. E. (1990) · International Journal of the Addictions · doi:10.3109/10826089009058870 · Cited by 18
Is a Single Dose of MDMA Harmless?
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1999) · DigitalGeorgetown (Georgetown University Library) · Cited by 13
The Pharmacology of Hallucinogens
Murphree, H. B. (1983) · Springer eBooks · doi:10.1007/978-1-4613-3626-6_5 · Cited by 11
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Psychobiology of Altered States of Consciousness.
Vaitl, D., Birbaumer, N., Gruzelier, J., Jamieson, G. A., Kotchoubey, B., Kübler, A., Lehmann, D., Miltner, W. H. R., Ott, U., Pütz, P., et al. (2005) · Psychological Bulletin · doi:10.1037/0033-2909.131.1.98 · Cited by 448
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Dumont, G. J. H., & Verkes, R. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063271 · Cited by 149
The neuropsychology of ecstasy (MDMA) use: a quantitative review.
Zakzanis, K. K., Campbell, Z., & Jovanovski, D. (2007) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.873 · Cited by 87
Metadata
- Authors
- Parrott, A. C.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 16
- Issue
- 8
- Pages
- 557-577
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2051226001
- Cited by
- 344
- References
- 111
- FWCI
- 27.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.